SundarJagannathMD

Hematologic Oncology

Mt. Sinai Myeloma Program

Overview of Dr. Jagannath

Dr. Sundar Jagannath is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including The Mount Sinai Hospital and Mount Sinai West. He received his medical degree from Baroda Medical College and has been in practice 41 years. Dr. Jagannath accepts several types of health insurance, listed below. He is one of 188 doctors at The Mount Sinai Hospital and one of 73 doctors at Mount Sinai West who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
10 E 102nd St
New York, NY 10029
Book by Phone+1(901) 621-8276

Fax+1 212-241-3908

Education & Training

University of Texas Health Science Center at HoustonResidency, Internal Medicine, 1980 - 1982
Wayne State University School of MedicineResidency, Internal Medicine, 1979 - 1980
BronxCare Health SystemResidency, Internal Medicine, 1977 - 1979
Baroda Medical CollegeClass of 1976

Certifications & Licensure

FL State Medical License 2017 - 2025
NJ State Medical License 2017 - 2025
NY State Medical License 1998 - 2025
MI State Medical License 1979 - 2020
TX State Medical License 1980 - 2011
AR State Medical License 1989 - 2000
MD State Medical License 1979 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2004, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma Start of enrollment: 2005 Jun 01
Completed
Phase 1
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma Start of enrollment: 2008 Dec 01
Withdrawn
Phase 1
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma Start of enrollment: 2007 May 01
Completed
Phase 1
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma Start of enrollment: 2008 Mar 01
Completed
Phase 2
Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma Start of enrollment: 2008 Sep 01
Terminated
Phase 2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Start of enrollment: 2013 Jan 01
Completed
Phase 2
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide Start of enrollment: 2011 Nov 01
Completed
Phase 1, Phase 2
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma Start of enrollment: 2012 Jan 01
Completed
Phase 1
Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) Start of enrollment: 2012 Jul 01
Completed
Phase 2
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib Start of enrollment: 2013 Sep 01
Completed
Phase 2
Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM Start of enrollment: 2019 Oct 24
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K Nooka
Blood. 2024-12-05
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients.
Lucia Y Chen, Santiago Thibaud, Saoirse Bodnar, Ajai Chari, Joshua Richter
Blood Advances. 2024-11-15
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
Sikander Ailawadhi, Hans C Lee, James Omel, Kathleen Toomey, James W Hardin
Blood Cancer Journal. 2024-11-11

Abstracts/Posters

A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
ADAR1 Drives Disease Progression in Multiple Myeloma By Acting Both As an RNA Editor of Specific Transcripts and As a DNA Mutator of Their Cognate Genes
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Sundar Jagannath, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Authored Content

Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients with Relapsed or Refractory Multiple MyelomaJune 2016

Press Mentions

$Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma$
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple MyelomaNovember 21st, 2022
$Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma: 2-Year Follow-up of CARTITUDE-1 Trial$
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma: 2-Year Follow-up of CARTITUDE-1 TrialJune 9th, 2022
$Carvykti Approved for Relapsed/Refractory Multiple Myeloma$
Carvykti Approved for Relapsed/Refractory Multiple MyelomaMarch 2nd, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
MagnaCare PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment